WHO on the use of CBD

OMS sobre el uso de CBD

WHO on the use of CBD: it is not addictive, nor harmful to health and has a multitude of therapeutic properties

“There is preliminary evidence that CBD may be a useful treatment for medical conditions [...] epilepsy, anxiety, inflammatory diseases, pain, nausea, etc…” This is what the Expert Committee on Drug Dependence of the World Health Organization has to say. This committee met in Geneva (Switzerland) from November 6 to 10, 2017 to analyze the therapeutic potential, adverse effects and potential dependence of CBD. The organization has published a report containing the conclusions of the expert professionals in cannabidiol . In addition to recognizing the potential of CBD in the treatment of epilepsy and other diseases, it recalls that "it is not listed in the United Nations International Drug Control Conventions of 1961, 1971 or 1988." Which means that: The United Nations does not consider this cannabinoid from Cannabis a drug . This report from the World Health Organization represents an important step in the path of medicinal Cannabis as it opens the door to new research based on the therapeutic potential of CBD. Below we summarise point by point the analysis and conclusions drawn by this commission.

CBD Expert Analysis Summary

  1. CBD is not addictive or harmful to health: It is noted that, according to studies carried out on animals, no tolerance has been identified nor have studies been reported that indicate physical dependence. The opposite effect has been identified. High doses do not affect the increase in dopamine release. Regarding the consequences of the potential abuse of this cannabinoid, according to the intracranial stimulation analyzed in mice, no adverse effects have been found due to the abusive use of CBD . From medical studies carried out with humans, it is extracted that CBD awakens the same addiction as the placebo . And that cannabidiol does not produce , by itself, any significant psychoactive or cardiovascular effect . They also conclude that CBD does not produce any negative consequences due to abuse.
  2. It does not cause social alarm: In the second point of the WHO report, it is acknowledged that no public concern has been identified regarding the use of CBD or accidents related to this substance.
  3. CBD has potential as a medicinal substance. The report notes that several advanced investigations have demonstrated its effectiveness against epilepsy and includes a list of other ailments for which CBD could be useful.

    Table of diseases for which CBD may have therapeutic benefits. (Source: WHO)

  4. Impact of the substance Based on the evidence, the WHO report concludes that CBD is not psychoactive, does not cause addiction and, in addition, has promising therapeutic uses , so they recommend continuing research on the subject.
Read the full report here

CBD, the cannabinoid that is legalizing Cannabis

Hemp oil has been sold in health food stores and health food shops for a long time. But CBD has a different story: In Europe, it is already legal in Switzerland and the United Kingdom, although the CBD wave is becoming global. This cannabinoid has already been removed from the World Anti-Doping Agency's prohibited list, allowing professional athletes to consume CBD since 2018. In this way, Cannabis, which does not have levels higher than 0.2 of THC, is leaving the prohibited lists of international organizations and becoming an ally for the physical conditioning of athletes. Companies specializing in CBD are beginning to emerge both nationally and internationally, which predict the advancement of regulation and the potential growth of the sector, marketing dermocosmetic products with CBD such as moisturizing creams with CBD , honey with CBD , balms with CBD , lip balms with CBD, especially CBD oil .

How is CBD used or administered?

CBD consumption is based on a personalized therapy according to each individual and the reason for use in each specific case, taking into account the regulatory framework of each country . As a general rule, the cannabinoid has no known adverse effects at any therapeutic dose, although this does not rule out the existence of certain pharmacological interactions to consider. The action of the active ingredient depends mainly on its kinetics in the body, with the release process being the most influential. In this case, oral release involves an action that takes longer (up to 30-90 minutes before the effect begins) and is also more prolonged (up to approximately 4 hours). Topical action has a localized action and can be beneficial for the treatment of inflammatory skin diseases such as: dermatitis, eczema, psoriasis and acne. Based on the many clinical and preclinical trials that have been carried out on the subject, a trial and error consumption over several days is recommended to allow for better correction according to the consumer's judgment . Small doses throughout the day are preferred over a single dose of a larger quantity or concentration of the substance. Currently, in countries where CBD regulation is advanced, consumers are mainly opting for formats such as CBD oil, marketed in various concentrations, the most common being 3% CBD Oils to30% CBD Oils. At The Beemine Lab we specialize in producing honey and CBD products. If you want to know more about CBD, check out our magazine. CBD and Anxiety CBD and Osteoarthritis CBD for Sleep CBD and Menstrual Pain CBD and Atopic Dermatitis CBD and Fibromyalgia The Endocannabinoid System Benefits of CBD for sports What is CBD? History, benefits and properties Sources:
  1. Annex 1- Extract from the Report of the 41st Expert Committee on Drug Dependence: Cannabis and cannabis-related substances. 2019
  2. CANNABIDIOL (CBD) Pre-Review Report. Expert Committee on Drug Dependence. Thirty-ninth Meeting. Geneva, 6-10 November. 2017
El CBD y la ansiedad
Previous CBD and anxiety
Next 3 ingredients to make masks with Honey and CBD
3 ingredientes para hacer mascarillas con Miel y CBD